40 results about "Phage therapy" patented technology

The present invention generally relates to engineered bacteriophages which express amyloid peptides for the modulation (e.g. increase or decrease) of protein aggregates and amyloid formation. In some embodiments, the engineered bacteriophages express anti-amyloid peptides for inhibiting protein aggregation and amyloid formation, which can be useful in the treatment and prevention of and bacterial infections and biofilms. In some embodiments, the engineered bacteriophages express amyloid peptides for promoting amyloid formation, which are useful for increasing amyloid formation such as promoting bacterial biofilms. Other aspects relate to methods to inhibit bacteria biofilms, and methods for the treatment of amyloid related disorders, e.g., Alzheimer's disease using an anti-amyloid peptide engineered bacteriophages. Other aspects of the invention relate to engineered bacteriophages to express the amyloid peptides on the bacteriophage surface and / or secrete the amyloid peptides, e.g., anti-amyloid peptides and pro-amyloid peptides, and uses thereof for modulation protein aggregates and amyloid formation.

The invention relates to a vibrio parahaemolyticus phage and a bactericidal composition containing the same. The phage can rapidly inhibit the growth of vibrios in a short time, and the duration of inhibition lasts long. In addition, the bactericidal composition of the phage is safe and effective, has strong specificity, is low in production cost, and makes up for the shortcoming of single phagotherapy in the control process of pathogenic bacteria.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245 / 05, F168 / 08, F170 / 08, F770 / 05, F197 / 08, F86 / 06, F87s / 06 and F91a / 06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and / or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.

The invention relates to an aeromonas salmonicida phage, a bactericidal composition containing the aeromonas salmonicida phage and application of the aeromonas salmonicida phage and the bactericidal composition. The phage can rapidly inhibit the growth of Atlantic aeromonas salmonicida in a short time and inhibit the generation of resistance to the pathogenic bacterium phage. In addition, the bactericidal composition of the phage is safe and effective and is high in specificity, the production cost is low, and the defects of a single phage therapy in a pathogen control process are made up.

The invention discloses staphylococcus aureus bacteriophage and application. The staphylococcus aureus bacteriophage and the application have the advantages that staphylococcus aureus can be specifically effectively eliminated by the staphylococcus aureus bacteriophage, excellent in-vivo and in-vitro antibacterial effects can be realized by the staphylococcus aureus bacteriophage for medicine-resistant staphylococcus aureus, experimental foundations can be provided to clinically developing preparations for preventing and treating medicine-resistant staphylococcus aureus infection, and the staphylococcus aureus bacteriophage has great clinical application potential; the skin abscess average areas of nude mice of bacteriophage treatment groups are 47.32 mm<2> in skin abscess models when MOI(multiplicity of infection) is equal to 10, and the average bacterium load is 3.553*10<7> CFU / g; the skin abscess average areas of nude mice of MRSA (methicillin-resistant staphylococcus aureus) infection groups are 150.4 mm<2>, and the average bacterium load is 2.284*10<8> CFU / g; the skin abscess areas of the mice of the bacteriophage treatment groups are smaller than the skin abscess areas of the mice of the MRSA infection groups, the colony count of the mice of the bacteriophage treatment groups is lower than the colony count of the mice of the MRSA infection groups, and the difference of the skin abscess areas and the colony count has statistical significance.

The invention relates to a lytic vibrio phage VspSw-1, a bactericidal composition containing the same and application thereof. The phage can rapidly inhibit vibrio growth within a short time, and theinhibiting effect lasts for a long time. In addition, the bactericidal composition of the phage is safe and effective, also has strong specificity, is low in production cost, and makes up for the shortcomings of single phage therapy in the control process of pathogenic bacteria.